Suchergebnisse - "Kazandjian, Dickran"

PubPharm (7)

1

MRD and Plasma Cell Dynamics after CAR T-cell Therapy in Myeloma

enthalten in: Blood cancer discovery | 2023

von Landgren, O. | Kazandjian, D.

CommentOn: Blood Cancer Discov. 2023 Sep 1;4(5):365-373. - PMID 37486974

2

Modern Myeloma Therapy + Sustained Minimal Residual Disease-Negative = (Functional) Cure!

enthalten in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2022

von Landgren, O. | Kazandjian, D.

CommentOn: J Clin Oncol. 2022 Sep 1;40(25):2889-2900. - PMID 35377708

3

Novel Quadruplets and the Age of Immunotherapies in the Treatment of Newly Diagnosed Multiple Myeloma

enthalten in: JAMA oncology | 2022

von Kazandjian, D. | Landgren, O.

CommentOn: JAMA Oncol. 2022 Sep 1;8(9):1278-1286. - PMID 35862034

4

Diagnosed with myeloma before age 40

enthalten in: Blood | 2021

von Landgren, O. | Kazandjian, D.

CommentOn: Blood. 2021 Dec 23;138(25):2686-2695. - PMID 34479366

5

Treatments for newly diagnosed multiple myeloma : when endurance is interrupted

enthalten in: The Lancet. Oncology | 2020

von Landgren, O. | Siegel, D. | Kazandjian, D. | +2

CommentOn: Lancet Oncol. 2020 Oct;21(10):1317-1330. - PMID 32866432

6

Differentiation Syndrome with Ivosidenib and Enasidenib Treatment in Patients with Relapsed or Refractory IDH-Mutated AML : A U.S. Food and Drug Administration Systematic Analysis

enthalten in: Clinical cancer research : an official journal of the American Association for Cancer Research | 2020

von Norsworthy, K. | Mulkey, F. | Scott, E. | +11

CommentIn: Clin Cancer Res. 2020 Aug 15;26(16):4174-4176. - PMID 32554513

7

Application of the Lung Immune Prognostic Index From Research to Clinical Practice-Reply

enthalten in: JAMA oncology | 2020

von Kazandjian, D. | Gong, Y. | Blumenthal, G.

CommentOn: JAMA Oncol. 2019 Jul 25;:. - PMID 31343662

1
[1]